Webcompetition by eliminating future competition between Hikma and Custopharm in the market for injectable TCA thereby (1) increasing the likelihood that the combined entity would forego the launch of Hikma’s injectable TCA product in development; and (2) increasing the likelihood that the combined entity would delay, reduce, or eliminate the WebApr 20, 2024 · Hikma Pharmaceuticals ( OTCPK:HKMPF) ( OTCPK:HKMPY ) said it received preliminary approval from the U.S. Federal Trade Commission for its its acquisition of Custopharm from Water Street Healthcare ...
Hikma completes acquisition of Custopharm - Yahoo Finance
WebJul 14, 2024 · Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Hikma Pharmaceuticals plc’s $375 million acquisition of Custopharm, Inc. likely would have harmed competition in the market for the corticosteroid drug triamcinolone acetonide, or TCA. WebSep 27, 2024 · 27 Sep, 2024 07:26 29 Jun, 2024 02:36 Hikma buys Custopharm for $375m Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt... inclusionary zoning ct
Hikma acquires US company Custopharm for $425m
WebSep 27, 2024 · Strengthens Hikma's platform for future growth. Custopharm is a growing business and Hikma expects it to generate full year 2024 revenue in excess of $80 million … WebApr 12, 2024 · Hikma, which means “wisdom” in Arabic, was founded in Jordan in 1978 and supplies various generic drugs including anaesthetics, pain medications, sedatives, neuromuscular blocking agents and anti-infectives. ... In April 2024, the company completed the acquisition of California-based Custopharm in a deal valued at $425 million, as part of ... WebApr 22, 2024 · Hikma Pharmaceuticals has acquired US-based generic sterile injectables company Custopharm from Water Street Healthcare Partners in a deal valued at $425m. … inclusionary zoning def